GSK looks unlikely to be a major player in COVID-19 vaccines, even in boosters, but its partnership with Vir could pay off handsomely.
GlaxoSmithKline has been playing catch-up in COVID-19 in 2021 and while partnerships in vaccines and therapeutics have just produced two encouraging results, only its antibody drug looks likely to make a big impact.
Partner Medicago has just announced results from a Phase II/III placebo-controlled study of its plant-derived COVID-19 vaccine in combination with GSK’s AS03 pandemic adjuvant, showing 75
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
